Cyclerion Therapeutics, Inc. (CYCN) - 10-Q Summary for Period Ended June 30, 2026
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on neuropsychiatric disorders. As of the reporting date, the Company has one employee and relies on consultants. The Company is currently in the process of a proposed merger with Korsana Biosciences, Inc., which, if completed, will result in Cyclerion changing its name to Korsana Biosciences, Inc. and Korsana's business becoming the primary operation.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Total Revenues | $0 | $174 |
| Net Loss | $(4,932) | $(1,753) |
| Net Loss Per Share (Basic & Diluted) | $(1.17) | $(0.62) |
| Cash and Cash Equivalents (End of Period) | $1,391 | $3,006 |
| Net Cash Used in Operating Activities | $(2,608) | $(1,471) |
| Total Assets | $6,930 | $9,985 |
| Accumulated Deficit | $(275,952) | $(269,245) |
Liquidity and Debt: The Company reported no long-term debt. Current liabilities totaled $1.843 million, primarily driven by accounts payable ($1.597 million). The Company holds an investment in Tisento Therapeutics Inc. valued at $5.35 million.
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped to zero for the six months ended June 30, 2026, compared to $174,000 in the prior year period. This is due to the termination of the Option Agreement for olinciguat in October 2025, which previously generated extension fees.
- Increased Net Loss: Net loss increased by 181% year-over-year to $4.932 million. This was driven by a significant increase in General and Administrative (G&A) expenses ($4.250 million vs. $3.211 million) due to legal fees related to the Merger, partially offset by a decrease in Research and Development (R&D) expenses ($730,000 vs. $92,000) as development efforts were suspended.
- Cash Burn: Cash and cash equivalents decreased by $1.849 million during the period. The Company utilized its At-The-Market (ATM) offering program to raise $825,000 in net proceeds in January 2026, exhausting its capacity under current public float limitations.
- Accounts Receivable: Accounts receivable decreased from $1.0 million to zero, reflecting the collection of a $1.0 million milestone payment from Akebia Therapeutics in February 2026 for the initiation of Phase 2 trials for praliciguat.
Outlook, Risks, and Management Commentary
- Merger with Korsana: The Company entered a Merger Agreement on April 1, 2026. Closing is anticipated in Q3 2026, contingent on shareholder approval and a concurrent $380 million pre-closing financing by Korsana. Upon closing, Cyclerion shareholders will receive Contingent Value Rights (CVRs) for potential future proceeds from legacy assets (praliciguat, Tisento equity).
- Going Concern Warning: Management has concluded that substantial doubt exists regarding the Company's ability to continue as a going concern. While current cash is expected to fund operations until the Merger closing, the Company will require additional funding if the Merger fails. If the Merger is not consummated, the Board may consider dissolution.
- Strategic Shift: Due to cash limitations, the Company has suspended efforts to advance its lead TRD program (CYC-126) and is focusing on monetizing legacy assets and completing the Merger.
- Risks: Key risks include the failure to obtain stockholder approval for the Merger, the failure of the Korsana Pre-Closing Financing, and the inability to raise capital if the Merger does not close. There is also uncertainty regarding the value of the CVRs and the Tisento investment.
Key Facts for Investor Verification
- Merger Status: Verify the progress of the Korsana Merger, specifically the status of the $380 million pre-closing financing and the upcoming shareholder vote.
- Cash Runway: Confirm the Company's cash burn rate and whether the $1.391 million cash balance is sufficient to reach the anticipated Q3 2026 closing date without additional dilutive financing.
- Legacy Asset Value: Assess the likelihood of future milestone payments from Akebia (praliciguat) and the potential liquidity of the Tisento Therapeutics equity stake, as these drive the value of the CVRs.
- Going Concern Mitigation: Review the specific plans management has to secure funding if the Merger is terminated, given the explicit "substantial doubt" disclosure.
- ATM Program Status: Note that the ATM program is currently exhausted due to public float limitations; verify if any new shelf registration has been filed to enable further equity raises.